Organogenesis(ORGO)

Focus: Organogenesis is a public biotech company focused on regenerative medicine and biologics, with a concentrated portfolio in wound care, orthopedic, and surgical applications. The company generates ~$433M in annual revenue with a lean R&D footprint (10% intensity).

Regenerative Medicine Biologics Wound Care Unknown

Profile data last refreshed 19h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

About Organogenesis

AI assessmentNot Hiring

No open roles listed right now. Follow Organogenesis to get notified when they start hiring — the background below is worth knowing for when they do.

Generated by Claude from Organogenesis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Data completeness

4/9 — Basic

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$433M

Pipeline & Clinical Trials

VCT-01

Wounds

N/A

Clinical Trials (1)

NCT01292122Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds

N/A

Help build intelligence for Organogenesis

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Affinity

Venous Leg Ulcer

N/A

Clinical Trials (1)

NCT04901013Clinical Study Of Affinity Versus SOC In The Management Of VLUs

N/A

NuShield

Tendon Injuries

N/A

Clinical Trials (2)

NCT07510412Clinical Trial Evaluating NuShield® Plus Standard of Care (SOC) Versus Standard of Care (SOC) Alone in the Management of Non-Healing Venous Leg Ulcers (VLUs)

N/A

NCT03828916NuShield in Surgical Peroneal Tendon Repair

N/A

One or two level lumbar interbody fusion surgery

Degenerative Disc Disease

N/A

Clinical Trials (1)

NCT02808234Study of Nucel for One and Two Level Lumbar Interbody Fusion

N/A

Affinity Allograft

Diabetic Foot Ulcers

N/A

Clinical Trials (1)

NCT02880592Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

N/A

PuraPly™ Antimicrobial Wound Matrix

Partial Thickness Wound

N/A

Clinical Trials (1)

NCT03286452The RESPOND Registry

N/A

NuCel with Autograft

Intervertebral Disc Disease

N/A

Clinical Trials (1)

NCT02023372Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine

N/A

Gintuit

Gingival Recession

N/A

Clinical Trials (1)

NCT01547962A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcer

N/A

Clinical Trials (1)

NCT03070938PuraPly™ Antimicrobial Wound Matrix and Wound Management

N/A

NuShield

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT03855514Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

N/A

Standard of Care

Diabetic Foot Ulcer

N/A

Clinical Trials (1)

NCT06618612A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

N/A

ReNu

Osteochondral Defect

N/A

Clinical Trials (1)

NCT03036878ReNu™ Marrow Stimulation Augmentation

N/A

PuraPly™ Antimicrobial Wound Matrix

Pressure Ulcers

N/A

Clinical Trials (1)

NCT03070925Prospective PuraPly™ AM Case Series Study